Cargando…

Neuroprotective Effect of Caffeine in Alzheimer’s Disease

Alzheimer’s disease (AD) is the leading cause of dementia, predicted to be the most significant health burden of the 21st century, with an estimated 131.5 million dementia patients by the year 2050. This review aims to provide an overview of the effect of caffeine on AD and cognition by summarizing...

Descripción completa

Detalles Bibliográficos
Autores principales:	M Yelanchezian, Y Mukish, Waldvogel, Henry J., Faull, Richard L. M., Kwakowsky, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227174/ https://www.ncbi.nlm.nih.gov/pubmed/35744865 http://dx.doi.org/10.3390/molecules27123737

Ejemplares similares

Effect of Estradiol on Neurotrophin Receptors in Basal Forebrain Cholinergic Neurons: Relevance for Alzheimer’s Disease
por: Kwakowsky, Andrea, et al.
Publicado: (2016)

Therapeutic potential of alpha 5 subunit containing GABA(A) receptors in Alzheimer’s disease
por: Kwakowsky, Andrea, et al.
Publicado: (2021)

Towards a Better Understanding of GABAergic Remodeling in Alzheimer’s Disease
por: Govindpani, Karan, et al.
Publicado: (2017)

Vascular dysfunction in Alzheimer’s disease: a biomarker of disease progression and a potential therapeutic target
por: Govindpani, Karan, et al.
Publicado: (2019)

Impaired Expression of GABA Signaling Components in the Alzheimer’s Disease Middle Temporal Gyrus
por: Govindpani, Karan, et al.
Publicado: (2020)

iGluR expression in the hippocampal formation, entorhinal cortex, and superior temporal gyrus in Alzheimer’s disease
por: Yeung, Jason HY, et al.
Publicado: (2022)

The effects of amyloid-beta on hippocampal glutamatergic receptor and transporter expression
por: Kwakowsky, Andrea, et al.
Publicado: (2020)

Vascular Dysfunction in Alzheimer’s Disease: A Prelude to the Pathological Process or a Consequence of It?
por: Govindpani, Karan, et al.
Publicado: (2019)

Gamma-aminobutyric acid A receptors in Alzheimer's disease: highly localized remodeling of a complex and diverse signaling pathway
por: Kwakowsky, Andrea, et al.
Publicado: (2018)

Glutamatergic receptor expression changes in the Alzheimer's disease hippocampus and entorhinal cortex
por: Yeung, Jason H. Y., et al.
Publicado: (2021)

The Role of Microglia and Astrocytes in Huntington’s Disease
por: Palpagama, Thulani H., et al.
Publicado: (2019)

Is Hormone Replacement Therapy a Risk Factor or a Therapeutic Option for Alzheimer’s Disease?
por: Mills, Zoe B., et al.
Publicado: (2023)

EAAT2 Expression in the Hippocampus, Subiculum, Entorhinal Cortex and Superior Temporal Gyrus in Alzheimer’s Disease
por: Yeung, Jason H. Y., et al.
Publicado: (2021)

Current and Possible Future Therapeutic Options for Huntington’s Disease
por: Ferguson, Mackenzie W., et al.
Publicado: (2022)

The Neuroprotective Effects of Moderate and Regular Caffeine Consumption in Alzheimer's Disease
por: Zhou, Xiangyu, et al.
Publicado: (2021)

mGluR1α expression in the hippocampus, subiculum, entorhinal cortex and superior temporal gyrus in Alzheimer’s disease
por: Yeung, J.H.Y., et al.
Publicado: (2022)

Sex- and age-related changes in GABA signaling components in the human cortex
por: Pandya, Madhavi, et al.
Publicado: (2019)

EAAT2 as a therapeutic research target in Alzheimer's disease: A systematic review
por: Wood, Oliver W. G., et al.
Publicado: (2022)

The Acute Effects of Amyloid-Beta(1–42) on Glutamatergic Receptor and Transporter Expression in the Mouse Hippocampus
por: Yeung, Jason H. Y., et al.
Publicado: (2020)

GABA(A) Receptors Are Well Preserved in the Hippocampus of Aged Mice
por: Palpagama, Thulani H., et al.
Publicado: (2019)

The effect of age and sex on the expression of GABA signaling components in the human hippocampus and entorhinal cortex
por: Ethiraj, Jayarjun, et al.
Publicado: (2021)

Cation-Chloride Cotransporters KCC2 and NKCC1 as Therapeutic Targets in Neurological and Neuropsychiatric Disorders
por: Lam, Patricia, et al.
Publicado: (2023)

Cardiorespiratory and Neuroprotective Effects of Caffeine in Neonate Animal Models
por: Mota-Rojas, Daniel, et al.
Publicado: (2023)

Antioxidant and Neuroprotective Effects of Caffeine against Alzheimer’s and Parkinson’s Disease: Insight into the Role of Nrf-2 and A2AR Signaling
por: Ikram, Muhammad, et al.
Publicado: (2020)

An α5 GABAA Receptor Inverse Agonist, α5IA, Attenuates Amyloid Beta-Induced Neuronal Death in Mouse Hippocampal Cultures
por: Vinnakota, Chitra, et al.
Publicado: (2020)

Beta-Amyloid (Aβ(1-42)) Increases the Expression of NKCC1 in the Mouse Hippocampus
por: Lam, Patricia, et al.
Publicado: (2022)

Neuroprotective Effects of Quercetin in Alzheimer’s Disease
por: Khan, Haroon, et al.
Publicado: (2019)

Amyloid-Beta(1-42) -Induced Increase in GABAergic Tonic Conductance in Mouse Hippocampal CA1 Pyramidal Cells
por: Calvo-Flores Guzmán, Beatriz, et al.
Publicado: (2020)

Potential Neuroprotective Effects of Adiponectin in Alzheimer’s Disease
por: Ng, Roy Chun-Laam, et al.
Publicado: (2017)

Study on the neuroprotective effects of Genistein on Alzheimer’s disease
por: Duan, Xiaoying, et al.
Publicado: (2021)

Impact of Caffeine on Alzheimer’s Disease Pathogenesis—Protective or Risk Factor?
por: Schreiner, Thomas Gabriel, et al.
Publicado: (2022)

Potential of Caffeine in Alzheimer’s Disease—A Review of Experimental Studies
por: Londzin, Piotr, et al.
Publicado: (2021)

Encephalopathy in Preterm Infants: Advances in Neuroprotection With Caffeine
por: Yang, Liu, et al.
Publicado: (2021)

The Neuroprotective Potentiality of Flavonoids on Alzheimer’s Disease
por: Calderaro, Antonella, et al.
Publicado: (2022)

Neuroprotective Herbs for the Management of Alzheimer’s Disease
por: Gregory, Julie, et al.
Publicado: (2021)

Neuroprotective Natural Products for Alzheimer’s Disease
por: Chen, Xin, et al.
Publicado: (2021)

Pretreatment of caffeine leads to partial neuroprotection in MPTP model of Parkinson's disease
por: Bagga, Puneet, et al.
Publicado: (2016)

Caffeine for Prevention of Alzheimer’s Disease: Is the A(2A) Adenosine Receptor Its Target?
por: Merighi, Stefania, et al.
Publicado: (2023)

The Neuroprotective Effects and Therapeutic Potential of the Chalcone Cardamonin for Alzheimer’s Disease
por: Barber, Kimberly, et al.
Publicado: (2023)

Graded perturbations of metabolism in multiple regions of human brain in Alzheimer's disease: Snapshot of a pervasive metabolic disorder
por: Xu, Jingshu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qc88h8pic7mv62olcka0fi18bt